Presentations, Posters & Publications

October 2021
AACR-NCI-EORTC: Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration
November 2020
CTOS Oral Presentation: The Potent and Selective KIT Inhibitor PLX9486 Dosed in Combination with Sunitinib Demonstrates Promising Progression Free Survival (PFS) in Patients with Advanced Gastrointestinal Stromal Tumor (GIST): Final Results of a Phase 1/2
June 2018
ASCO: A phase I pharmacokinetic and pharmacodynamic study of PLX9486 alone and in combination with the KIT inhibitors pexidartinib (pexi) or sunitinib in patients with advanced solid tumors and gastrointestinal stromal tumor (GIST)
November 2017
CTOS: A Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of PLX9486, A Novel KIT Inhibitor with Potent Activity Against Exon 17/18 Activation Loop Mutations in Patients with Gastrointestinal Stromal Tumor (GIST)
More information is coming soon.